Dhaon Pooja, Shah Viral N
Department of Rheumatology, King George Medical University, Lucknow, Uttar Pradesh, India.
Barbara Davis Center for Diabetes, University of Colorado, CO, USA.
Indian J Endocrinol Metab. 2014 Mar;18(2):159-65. doi: 10.4103/2230-8210.129105.
With better care and intensive insulin therapy, microvascular complications have reduced and longevity has increased in patients with type 1 diabetes (T1DM). Therefore, there is a need to change the focus from microvascular complications to cardiovascular disease and osteoporosis. Though number of studies from other parts of the world show that patients with T1DM are at increased risk of osteoporosis and fractures, there is a paucity of data from India. A number of factors and mechanisms affecting bone health in patients with T1DM have been proposed. The main defect in genesis of osteoporosis is osteoblastic function, rather than osteoclastic overfunction. Assessment of bone mineral density by dual X-ray absorptiometry and other risk factors for osteoporosis, as a part of diagnostic procedure can help to design tailored treatment plans. A physically active healthy lifestyle, prevention of diabetic complications and adequate calcium and vitamin D supplementation are the mainstay for prevention of osteoporosis. Treatment of osteoporosis is not evidence based but it is proposed to be similar to osteoporosis associated with other conditions. Bisphosphonates are the mainstay for treatment of osteoporosis in patients with T1DM. However, more studies are needed to make definitive guidelines on prevention and treatment of osteoporosis in patients with T1DM.
随着护理水平的提高和强化胰岛素治疗,1型糖尿病(T1DM)患者的微血管并发症有所减少,寿命得以延长。因此,有必要将关注重点从微血管并发症转向心血管疾病和骨质疏松症。尽管世界其他地区的多项研究表明,T1DM患者患骨质疏松症和骨折的风险增加,但印度的数据却很匮乏。已经提出了许多影响T1DM患者骨骼健康的因素和机制。骨质疏松症发生的主要缺陷在于成骨细胞功能,而非破骨细胞功能亢进。作为诊断程序的一部分,通过双能X线吸收法评估骨密度以及其他骨质疏松症风险因素,有助于制定个性化的治疗方案。积极健康的生活方式、预防糖尿病并发症以及充足的钙和维生素D补充是预防骨质疏松症的主要措施。骨质疏松症的治疗尚无循证依据,但建议其治疗方法与其他相关病症引起的骨质疏松症类似。双膦酸盐是T1DM患者骨质疏松症治疗的主要药物。然而,需要更多研究来制定关于T1DM患者骨质疏松症预防和治疗的明确指南。